Australien - engelsk - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 5.21 mg (equivalent: rosuvastatin, qty 5 mg) - tablet, film coated - excipient ingredients: crospovidone; meglumine; lactose monohydrate; pregelatinised starch; purified water; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; triacetin; iron oxide yellow - rosuvastatin mc should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin mc is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin mc is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin mc is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin mc, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 41.68 mg (equivalent: rosuvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; meglumine; pregelatinised starch; microcrystalline cellulose; purified water; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - rosuvastatin mc should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin mc is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin mcis indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin mc is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin mc, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 20.84 mg (equivalent: rosuvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: meglumine; magnesium stearate; purified water; microcrystalline cellulose; lactose monohydrate; pregelatinised starch; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - rosuvastatin mc should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin mc is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin mc is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin mc is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin mc, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 5.21 mg (equivalent: rosuvastatin, qty 5 mg) - tablet, film coated - excipient ingredients: meglumine; lactose monohydrate; purified water; pregelatinised starch; magnesium stearate; microcrystalline cellulose; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide yellow - rosuvastatin mc should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin mc is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin mc is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin mc is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin mc, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 10.42 mg (equivalent: rosuvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; purified water; pregelatinised starch; microcrystalline cellulose; meglumine; magnesium stearate; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - rosuvastatin mc should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin mc is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin mc is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin mc is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin mc, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Indien - engelsk - Central Drugs Standard Control Organization

mercury hc. - dried alum.hydrox.gel,mag.hydrox.,simethicone - gel sus - 400,400,50;mg - 170ml

Indien - engelsk - Central Drugs Standard Control Organization

curex - nandrolone phenylpropionate - inj - 25mg - v.

Indien - engelsk - Central Drugs Standard Control Organization

brooks ph. - syr - 200ml

Filippinerne - engelsk - FDA (Food And Drug Administration)

medical center trading corp. - first aid kit - kit

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pacific dental specialties pty ltd - 46645 - membrane fixation tack, non-biodegradable - this is a sterile non-biodegradable tack (screw) intended to be used to be driven into bone to fix or stabilize biodegradable barrier membranes used for the regeneration of tissue and/or bone or other devices used within the oral cavity, or used for other clinical situations that require membrane utilization.